drugset / Trial / NCT04565574
A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will have three parts: Part A, Part B, and Part C. The primary purpose of Part A is to evaluate the effect of food on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part B is to evaluate the effects of rabeprazole (a gastric acid-reducing agent) on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part C is to evaluate the effects of rifampin (a strong Cytochrome P450 3A \[CYP3A\] inducer) on pharmacokinetics (PK) of single oral doses of E7090 in healthy participants.
Timeline
- Start
- 2020-10-16
- Primary completion
- 2021-03-31
- Completion
- 2021-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | E7090 | Small molecule | 35 mg | Oral |
| Subject | Rabeprazole | Small molecule | 20 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |
Indications
No indication recorded.